Resumen
PCT No. PCT/ES95/00024 Sec. 371 Date Mar. 27, 1996 Sec. 102(e) Date Mar. 27, 1996 PCT Filed Feb. 24, 1995 PCT Pub. No. WO95/23145 PCT Pub. Date Aug. 31, 1995Said derivatives have the general formula (I) and are: <IMAGE> (I) (I-A) 4,6,7-trimethyl-5,8,8a,10a-tetrahydro-1H-1-azaanthracen-2,9,10-trione; (I-B) 2-ethoxy-3-methyl-1-azaanthracen-9,10-dione; (I-C) 3-ethyl-1,8-dihydro-1H-1,8-diazaanthracen-2,7,9,10-tetraone; (I-d) 2-acethoxy-3-methyl-1,8-diazaanthracen-2,9,10-trione; (I-e) 6-fluor-4-methyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-f) 6-dimethylamino-4-methyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-g) 4-methyl-5-(2-nitrophenyl)-5,8-dihydro-1H-1,8-diazaanthracen-2,9,10-trione; (I-h) 3,5-dimethyl-1,8-dihydro-1,8-diazaanthracen-2,7,9,10-tetraone; (I-i) 3,6-difluor-1,8-diazaanthracen-9,10-dione; (I-j) 6-methyl-3-phenyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-k) 3-fluor-4-methyl-1-dihydro-1-azaanthracen-9,10-dione; 3-fluor-1-azaanthracen-1,10-dione. Application as antitumor agents.
Reivindicaciones
1. new anthraquinonic derivatives having antitumor activity, characterized in that they have the following general formula (I): <img class="EMIRef" id="429140160-ib0010" /> wherein the broken line represents a double bond that may or may not be present and A and B form, together with the center ring, an anthraquinonic system that responds to the following pairs of meanings A and B: <img class="EMIRef" id="429140160-ib0011" /> <img class="EMIRef" id="429140160-ib0012" /> the broken line representing a double bond in all cases except in (a) in which said double bond is not present. 2. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-a): <img class="EMIRef" id="429140160-ib0013" /> 3. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-b): <img class="EMIRef" id="429140160-ib0014" /> 4. New anthraquinonic derivative, accoording to claim 1, characterized in that it has the following formula (I-c): <img class="EMIRef" id="429140160-ib0015" /> 5. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-d): <img class="EMIRef" id="429140160-ib0016" /> 6. New anthraquinonic derivative, according to claim 1, characererized in that it has the following formula (I-e): <img class="EMIRef" id="429140160-ib0017" /> 7. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-f): <img class="EMIRef" id="429140160-ib0018" /> 8. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-g): <img class="EMIRef" id="429140160-ib0019" /> 9. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-h): <img class="EMIRef" id="429140160-ib0020" /> 10. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-i): <img class="EMIRef" id="429140160-ib0021" /> 11. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-j): <img class="EMIRef" id="429140160-ib0022" /> 12. New anthraquinonic derivative, according to claim 1, characerterized in that it has the following formula (I-k): <img class="EMIRef" id="429140160-ib0023" /> 13. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-l): <img class="EMIRef" id="429140160-ib0024" /> 14. Application of the anthraquinonic derivatives of formula (I) defined in claim 1 as antitumor agents. 15. Application of the anthraquinonic derivative of formula (I-a) of claim 2 as an antitumor agent. 16. Application of the anthraquinonic derivative of formula (I-b) of claim 3 as an antitumor agent. 17. Application of the anthraquinonic derivative of formula (I-c) of claim 4 as an antitumor agent. 18. Application of the anthraquinonic derivative of formula (I-d) of claim 5 as an antitumor agent. 19. Application of the anthraquinonic derivative of formula (I-e) of claim 7 as an antitumor agent. 20. Application of the anthraquinonic derivative of formula (I-f) of claim 7 as an antitumor agent. 21. Application of the anthraquinonic derivative of formula (I-g) of claim 8 as an antitumor agent. 22. Application of the anthraquinonic derivative of formula (I-h) of claim 9 as an antitumor agent. 23. Application of the anthraquinonic derivative of formula (I-i) of claim 10 as an antitumor agent. 24. Application of the anthraquinonic derivative of formula (I-j) of claim 11 as an antitumor agent. 25. Application of the anthraquinonic derivative of formula (I-k) of claim 12 as an antitumor agent. 26. Application of the anthraquinonic derivative of formula (I-l) of claim 12 as an antitumor agent. 27. Application of any one of the anthraquinonic derivatives of formulae (I-a) to (I-l) defined in the above claims 2 to 13 for the manufacture of drugs for the treatment of tumors.
